Prognostic factors in patients after definitive chemoradiation using involved‐field radiotherapy for esophageal cancer in a phase II study

Autor: Hideomi Yamashita, Ryousuke Takenaka, Kae Okuma, Kuni Ootomo, Keiichi Nakagawa
Rok vydání: 2016
Předmět:
Male
Esophageal Neoplasms
Organoplatinum Compounds
medicine.medical_treatment
Gastroenterology
chemistry.chemical_compound
0302 clinical medicine
Antineoplastic Combined Chemotherapy Protocols
esophageal cancer
Prospective Studies
Prospective cohort study
Aged
80 and over
Univariate analysis
General Medicine
Middle Aged
Esophageal cancer
Prognosis
Primary tumor
Treatment Outcome
Oncology
Lymphatic Metastasis
030220 oncology & carcinogenesis
Original Article
Female
030211 gastroenterology & hepatology
Fluorouracil
Adult
Pulmonary and Respiratory Medicine
medicine.medical_specialty
gross tumor volume
relative dose intensity
Definitive chemoradiotherapy
Disease-Free Survival
Young Adult
03 medical and health sciences
Internal medicine
medicine
Humans
Nedaplatin
Aged
involved‐field radiotherapy
business.industry
Dose fractionation
Original Articles
medicine.disease
Radiation therapy
chemistry
Dose Fractionation
Radiation
Neoplasm Grading
business
Nuclear medicine
Chemoradiotherapy
Zdroj: Thoracic Cancer
ISSN: 1759-7714
1759-7706
Popis: Background A prospective study was performed on the use of chemoradiotherapy (CRT) for esophageal cancer (EC) with involved‐field radiation therapy (IFRT), based on 18‐fluorodeoxyglucose positron‐emission tomography. Prognostic factors for overall survival (OS) were analyzed. Methods Eligible patients included 63 adults with newly diagnosed, untreated, inoperable stage I–IV EC with lymph node metastases. Patients received 80 mg/m2 nedaplatin per day on day 1, 800 mg/m2 5‐fluorouracil on days 1–4 intravenously repeated every 28 days for two to four cycles, and combined IFRT. Irradiation was applied only to the primary tumor and positive lymph nodes. Results Three‐year progression‐free survival and OS rates were 44.9% and 47.5%, respectively. The median survival time was 31.5 months. In univariate analyses for OS, Karnofsy Performance Scale 1.5 ng/mL (P = 0.0054), gross tumor volume (GTV) > 60 cc (P = 0.00011), and relative dose intensity (RDI) of chemotherapy ≤50% (P = 0.063) were found to be associated with significantly or marginally worse OS. In multivariate analyses for OS, GTV ≥ 60 cc (P = 0.00040), RDI < 50% (P = 0.00034), and cN2‐3 (P = 0.0020) were associated with significantly worse OS. Conclusion GTV, RDI and N grading, were associated with OS after definitive CRT using IFRT for EC.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje